Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Cancer Treatment Reviews|June 22, 2025
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging StrategiesFederica Giugliano, Carmine De Angelis, Barbara Pistilli, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast CancerRinath Jeselsohn, William T Barry, Ilenia Migliaccio, et al.
NPJ Breast Cancer|March 8, 2025
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancerRiccardo Scandino, Agostina Nardone, Nicola Casiraghi, et al.
Briefings in Bioinformatics|January 18, 2023
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samplesDario Romagnoli, Agostina Nardone, Francesca Galardi, et al.
JCO Precision Oncology|March 1, 2024
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd TrialIlenia Migliaccio, Dario Romagnoli, Francesca Galardi, et al.
Translational Oncology|November 20, 2022
Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patientsEmanuela Risi, Camilla Lisanti, Alessia Vignoli, et al.
Journal of the National Cancer Institute|December 10, 2013
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trialAngelo Di Leo, Guy Jerusalem, Lubos Petruzelka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancerMichele De Laurentiis, Grazia Arpino, Erminia Massarelli, et al.
Therapeutic Advances in Medical Oncology|December 20, 2019
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)Emanuela Risi, Chiara Biagioni, Matteo Benelli, et al.
Pageof 7